Effect of adeforvir dipivoxil on the frequency of HBcAg-specific cytotoxic T cells in patients with chronic hepatitis B

World Chinese Journal of Digestology

Volumn 17, Issue 19, 2009, Pages 1996-1999

  Yan, Jie ^a   Xie, Wen ^a   Lin, Ya Hui ^b   Feng, Xin ^a   Wang, Bei Bei ^a   Xiao, Jiang ^a   Ou, Wei Ni ^a   Wang, Yan Bin ^a   Cheng, Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Adeforvir dipivoxil; Chronic hepatitis B; Cytotoxic T lymphocyte; MHC class I peptide tetramer

Indexed keywords

ADEFORVIR DIPIVOXIL; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN; HLA A2 ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE DISEASE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC DISEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONGITUDINAL STUDY; STAINING; TREATMENT DURATION; TREATMENT INDICATION;

EID: 70349513491     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v17.i19.1996     Document Type: Article

References (11)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
2. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229
3. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002; 2: 43-50
4. Garboczi DN, Hung DT, Wiley DC. HLA-A2- peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A 1992; 89: 3429-3433
5. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565-1570
6. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971 (Pubitemid 32246646)
7. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605 (Pubitemid 37204661)
8. Wu Z, Yan W, Guo W, Zou Y, Wang H, Ning Q. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model. The 59th Annual Meeting of AASLD, Moscone West Convention Center, San Francisco, Oct 31-Nov 4, 2008: Abstract 18